Innovation is Key

Child Formulation

The Pediatric Formulation Gap

Pharma's Almanac

Pathfinder

Conventional Peptide Synthesis vs. Recombinant Peptide Production: Which Manufacturing Strategy Is Better?

Nice Insight

Productivity

The Next Productivity Leap in Mammalian Cell Culture

Pharma's Almanac

Development CDMO

The Case for Earlier CDMO Involvement in Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Capacity

Is the Bioreactor Arms Race Over?

David Alvaro, Ph.D.

Pharma's Almanac

Biologics

Commercial Thinking Begins in Clinical Phases

Mathias Kahl

IDT Biologika

TPDs

Low Dose, High Impact: Microdosing, Content Uniformity, and Precision Control in TPDs

David O’Connell

PCI Pharma Services

Lipase Risk

An Integrated Analytical Approach to Lipase Risk Management in Biologics Development

Kyeyeon Hur, Ph.D.; Jimin Kim, Ph.D.; Minjeong Lee; Soojeong Oh; Woojung Jun

Samsung Biologics

Partner Selection

How are organizations balancing cost with regulatory, supply chain, and reputational risk when selecting partners or sites?

Pharma's Almanac